Aurinia Pharmaceuticals AUPH Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's financing cash flow?
- Aurinia Pharmaceuticals (AUPH) reported financing cash flow of -$53.69M in Q1 2026.
- How has Aurinia Pharmaceuticals's financing cash flow changed year-over-year?
- Aurinia Pharmaceuticals's financing cash flow decreased by 8.8% year-over-year, from -$49.34M to -$53.69M.
- What is the long-term trend for Aurinia Pharmaceuticals's financing cash flow?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's financing cash flow has grown at a -16.8% compound annual growth rate (CAGR), from $221.11M to -$106.11M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.